For internal use only, not for distribution.

# Implementing Decolonization in Nursing Homes to Prevent MDROs and Hospitalizations

Susan Huang, MD MPH
Chancellor's Professor, Division of Infectious Diseases
Medical Director, Epidemiology & Infection Prevention
University of California Irvine School of Medicine

### The High Risk of Infections in Nursing Homes

- 1.3 million persons receive care in U.S. nursing homes each year
- On average, each resident has at least 2 infections per year
- Every year, nursing home residents experience:
  - 2 to 3 million nursing home-associated infections
  - 150,000 infection-related hospitalizations
  - 380,000 infection-related deaths

# The Rise of MultiDrug-Resistant Organisms (MDROs)

In addition, there has been a steady rise of MDROs in healthcare

- Methicillin Resistant Staphylococcus aureus (MRSA)
- Vancomycin Resistant Enterococcus (VRE)
- MultiDrug-Resistant Pseudomonas
- Extended Spectrum Beta Lactamase Producers (ESBLs)
- Carbapenem Resistant Enterobacterales (CRE)
- Carbapenem Resistant Acinetobacter baumanii (CRAB)
- Candida auris

### **MDROs in Nursing Homes**

Approximately 10-15% of hospitalized patients harbor an MDRO In nursing homes, 50-65% of residents harbor an MDRO High prevalence in nursing homes may be related to:

- Shared activities
- Shared rooms
- Longer lengths of stay
- More chronic illness and devices, including feeding tubes
- Less stringent hand hygiene, contact precautions vs hospitals

#### What is Decolonization and How Does It Work?

### **Decolonization: Pathogen Burden Reduction**

**Decolonization:** use of topical antiseptic soaps and nasal ointments to reduce the body's bacteria during high-risk times for infection

#### Moments when our body bacteria becomes our own worst enemy

- Surgery
- Wounds
- Devices
- Difficulty with hygiene, clearance of secretions
- Hospitalization and nursing home stays

### Why is Decolonization Needed?

Because human pathogen transmission is a cascade of unfortunate events

- > Humans shed pathogens
  - > Environment is contaminated
    - Contamination persists
      - > Failure to clean or disinfect
        - Staff acquires pathogen
          - Staff fails to remove
            - > Transfers to patient
              - Risk for infection

### **Interventions to Prevent Transmission**

> Humans shed pathogens



**Prevents shedding** 

- > Environment is contaminated
  - Contamination persists
    - > Failure to clean or disinfect
      - Staff acquires pathogen
        - Staff fails to remove
          - Transfers to patient

**Broad solution for all MDROs Benefits carriers too** 

Risk for infection

#### Which Products?

- Most common products:
  - chlorhexidine gluconate (CHG)
  - iodophor (povidone-iodine)
  - Mupirocin
- Work better than soap and water
- Years of use in healthcare:
  - CHG: >60 years
  - iodophor: >60 years
  - Mupirocin >20 years

# Prior Precedence: Clinical Trial Evidence for Decolonization in Hospitals

### **Use of Chlorhexidine**

The NEW ENGLAND JOURNAL of MEDICINE

- Antiseptic uses in healthcare
  - ➤ Hand antisepsis at 2% and 4%
  - > Dental hygiene
  - > 1990s: Cleaning of skin prior to line i
  - > 1990s: Pre-operative bathing
  - 2000s: Surgical prep
  - > 2000s: Pre-op *S. aureus* carriers
  - > 2010s: Universal ICU bathing
  - > 2019: CHG for non-ICU bathing
  - ➤ 2019: Post-discharge CHG + mupirocin for MRSA

For internal use only, not for distribution.

#### ORIGINAL ARTICLE

### Effect of Daily Chlorhexidine Bathing on Hospital-Acquired Infection

Michael W. Climo, M.D., Deborah S. Yokoe, M.D., M.P.H., David K. Warren, M.D., Trish M. Perl, M.D., Maureen Bolon, M.D., Loreen A. Herwaldt, M.D., Robert A. Weinstein, M.D., Kent A. Sepkowitz, M.D., John A. Jernigan, M.D., Kakotan Sanogo, M.S., and Edward S. Wong, M.D.

# The NEW ENGLAND JOURNAL of MEDICINE

ESTABLISHED IN 1812

JUNE 13, 2013

OL. 368 NO. 24

#### Targeted versus Universal Decolonization to Prevent ICU Infection

Susan S. Huang, M.D., M.P.H., Edward Septimus, M.D., Ken Kleinman, Sc.D., Julia Moody, M.S., Jason Hickok, M.B.A., R.N., Taliser R. Avery, M.S., Julie Lankiewicz, M.P.H., Adrijana Gombosev, B.S., Leah Terpstra, B.A., Fallon Hartford, M.S., Mary K. Hayden, M.D., John A. Jernigan, M.D., Robert A. Weinstein, M.D., Victoria J. Fraser, M.D., Katherine Haffenreffer, B.S., Eric Cui, B.S., Rebecca E. Kaganov, B.A., Karen Lolans, B.S., Jonathan B. Perlin, M.D., Ph.D., and Richard Platt, M.D., for the CDC Prevention Epicenters Program and the AHRQ DECIDE Network and Healthcare-Associated Infections Program\*

THE LANCET

Daily chlorhexidine bathing to reduce bacteraemia in critically ill children: a multicentre, cluster-randomised, crossover trial

Aaron M Milstone, Alexis Elward, Xiaoyan Song, Danielle M Zerr, Rachel Orscheln, Kathleen Speck, Daniel Obeng, Nicholas G Reich, Susan E Coffin, Trish M Perl, for the Pediatric SCRUB Trial Study Group

#### Summar

Background Bacteraemia is an important cause of morbidity and mortality in critically ill children. Our objective was to assess whether daily bathing in chlorhexidine gluconate (CHG) compared with standard bathing practices would reduce bacteraemia in critically ill children.

### **Use of Chlorhexidine**

- Antiseptic uses in healthcare
  - Hand antisepsis at 2% and 4%
  - Dental hygiene
  - > 1990s: Cleaning of skin prior to line insertion
  - > 1990s: Pre-operative bathing
  - > 2000s: Surgical prep
  - > 2000s: Pre-op *S. aureus* carriers
  - > 2010s: Universal ICU bathing
  - > 2019: CHG for non-ICU bathing

#### > 2019: Post-discharge CHG + mupirocin for MRSA carriers

#### THE LANCET

Chlorhexidine versus routine bathing to prevent multidrug-resistant organisms and all-cause bloodstream infections in general medical and surgical units (ABATE Infection trial): a cluster-randomised trial

Susan S Huang, Edward Septimus, Ken Kleinman, Julia Moody, Jason Hickok, Lauren Heim, Adrijana Gombosev, Taliser R Avery, Katherine Haffenreffer, Lauren Shimelman, Mary K Hayden, Robert A Weinstein, Caren Spencer-Smith, Rebecca E Kaqanov, Michael V Murphy, Tyler Forehand, Julie Lankiewicz, Micaela H Coady, Lena Portillo, Jalpa Sarup-Patel, John A Jerniqan, Jonathan B Perlin, Richard Platt, for the ABATE Infection trial team

### **Use of Chlorhexidine**

- Antiseptic uses in healthcare
  - ➤ Hand antisepsis at 2% and 4%
  - Dental hygiene
  - > 1990s: Cleaning of skin prior to line insertion
  - > 1990s: Pre-operative bathing
  - ➤ 2000s: Surgical prep
  - > 2000s: Pre-op *S. aureus* carriers
  - ➤ 2010s: Universal ICU bathing
  - > 2019: CHG for non-ICU bathing

The NEW ENGLAND JOURNAL of MEDICINE

#### ORIGINAL ARTICLE

#### Decolonization to Reduce Postdischarge Infection Risk among MRSA Carriers

S.S. Huang, R. Singh, J.A. McKinnell, S. Park, A. Gombosev, S.J. Eells, D.L. Gillen, D. Kim, S. Rashid, R. Macias-Gil, M.A. Bolaris, T. Tjoa, C. Cao, S.S. Hong, J. Lequieu, E. Cui, J. Chang, J. He, K. Evans, E. Peterson, G. Simpson, P. Robinson, C. Choi, C.C. Bailey, Jr., J.D. Leo, A. Amin, D. Goldmann, J.A. Jernigan, R. Platt, E. Septimus, R.A. Weinstein, M.K. Hayden, and L.G. Miller, for the Project CLEAR Trial

> 2019: Post-discharge CHG + mupirocin for MRSA carriers

## **Universal Decolonization Trials in Hospitals**

Trial	Setting	N	Intervention	Decolonization Impact
Climo et al. ICU Trial <sup>1</sup>	7 Academic Hospitals 9 Adult ICUs	7700	Daily CHG	23% I MRSA/VRE acquisition 28% I Bloodstream infections
Pediatric Scrub Trial <sup>2</sup>	5 Academic Hospitals 10 Pediatric ICUs	1500	Daily CHG	36% J Bloodstream infections
REDUCE MRSA Trial <sup>3</sup>	43 Community Hospitals 74 Adult ICUs	74,000	Daily CHG 5d bid mupirocin	37%  ■ MRSA clinical cultures 44% ■ Bloodstream infections
Mupirocin-lodophor Swap Out Trial <sup>4</sup>	137 Community Hospitals 233 Adult ICUs	353,000	Mupirocin-CHG vs Iodophor-CHG	Mupirocin superior to lodophor by 18% for <i>S. aureus</i> ; 14% for MRSA
ABATE Infection Trial <sup>5</sup>	53 Community Hospitals 194 Adult Non-ICUs	340,000	Daily CHG Mupirocin if MRSA+	Subset effect in patients with devices:  37%    MRSA/VRE clinical cultures  32%   Bloodstream infections
CLEAR Trial <sup>6</sup>	Post Hospital Discharge	2,100	CHG, Mupirocin qoweek x 6 mo	30% MRSA Infection at 1y 17% All infection; 85% rehospitalized

<sup>&</sup>lt;sup>1</sup>Climo MW et al. NEJM 2013;368:533-542

<sup>&</sup>lt;sup>2</sup> Milstone AM et al. Lancet 2013:381(9872):1099-1106

<sup>&</sup>lt;sup>3</sup> Huang SS et al. NEJM 2013:368:2255-2265 For internal use only, not for distribution.

<sup>&</sup>lt;sup>4</sup> Huang SS et al. JAMA 2023;330(14):1337-1347

<sup>&</sup>lt;sup>5</sup> Huang SS et al. Lancet 2019;393(10177):1205-1215

<sup>&</sup>lt;sup>6</sup> Huang SS et al. NEJM 2019:380:638-650

### The Evidence for Decolonization in Nursing Homes

### The Evidence

#### Two studies

- SHIELD Regional Collaborative
- Protect Trial

The NEW ENGLAND JOURNAL of MEDICINE

#### ORIGINAL ARTICLE

#### Decolonization in Nursing Homes to Prevent Infection and Hospitalization

L.G. Miller, J.A. McKinnell, R.D. Singh, G.M. Gussin, K. Kleinman, R. Saavedra, J. Mendez, T.D. Catuna, J. Felix, J. Chang, L. Heim, R. Franco, T. Tjoa, N.D. Stone, K. Steinberg, N. Beecham, J. Montgomery, D.A. Walters, S. Park, S. Tam, S.K. Gohil, P.A. Robinson, M. Estevez, B. Lewis, J.A. Shimabukuro, G. Tchakalian, A. Miner, C. Torres, K.D. Evans, C.E. Bittencourt, J. He, E. Lee, C. Nedelcu, J. Lu, S. Agrawal, S.G. Sturdevant, E. Peterson, and S.S. Huang

Research

#### JAMA | Original Investigation


### Reducing Hospitalizations and Multidrug-Resistant Organisms via Regional Decolonization in Hospitals and Nursing Homes

Gabrielle M. Gussin, MS; James A. McKinnell, MD; Raveena D. Singh, MA; Loren G. Miller, MD, MPH; Ken Kleinman, ScD; Raheeb Saavedra, AS; Thomas Tjoa, MPH, MS; Shruti K. Gohil, MD, MPH; Tabitha D. Catuna, MPH; Lauren T. Heim, MPH; Justin Chang, MD; Marlene Estevez, BA; Jiayi He, MS; Kathleen O'Donnell, MPH; Matthew Zahn, MD; Eunjung Lee, MD, PhD; Chase Berman, BS; Jenny Nguyen, BA; Shalini Agrawal, BS; Isabel Ashbaugh, MSc; Christine Nedelcu, BS; Philip A. Robinson, MD; Steven Tam, MD; Steven Park, MD, PhD; Kaye D. Evans, BA, MT; Julie A. Shimabukuro, BS; Bruce Y. Lee, MD, MBA; Emily Fonda, MD, MMM; John A. Jernigan, MD, MS; Rachel B. Slayton, PhD, MPH; Nimalie D. Stone, MD, MS; Lynn Janssen, MS; Robert A. Weinstein, MD; Mary K. Hayden, MD; Michael Y. Lin, MD, MPH; Ellena M. Peterson, PhD; Cassiana E. Bittencourt, MD; Susan S. Huang, MD, MPH; for the CDC Safety and Healthcare Epidemiology Prevention Research Development (SHEPheRD) Program

### **SHIELD OC: 35 Facility Decolonization Intervention**

- 28-month regional intervention: April 2017-July 2019
- Participants: 16 nursing homes (NHs), 3 long-term acute care hospitals (LTACHs),
   16 hospitals with high patient sharing in Orange County, CA
- NHs and LTACHs: universal decolonization
  - ✓ Chlorhexidine (CHG) antiseptic soap for routine bathing/showering
  - ✓ Nasal iodophor for 5d on admission and every other week
- Hospitals: decolonize patients on contact precautions
  - ✓ Daily CHG bathing/showering
  - ✓ Nasal iodophor decolonization for 5 days
  - ✓ Support ongoing ICU CHG daily bathing

### **SHIELD Nursing Home Impact: 23% MDRO Reduction**



For internal use only, not for distribution. Gussin G et al. JAMA Online ahead of print. April 1, 2024

Figure 1. MDRO Point Prevalence (Screening) Among Facilities Participating in the Regional Decolonization Collaborative, Baseline and End of Intervention

Baseline			Intervention					
Colonization	No. of MDRO- positive persons	Mean (SD) prevalence across facilities, %	No. of MDRO- positive persons	Mean (SD) prevalence across facilities, %	OR (95% CI)	Less likely to be MDRO-positive	More likely to be MDRO-positive	P value
lursing homes								
Any MDRO	511	63.9 (12.2)	709	49.9 (11.3)	0.77 (0.69-0.86)	₩		<.001
Nares	236	29.5 (7.3)	360	25.1 (8.6)	0.84 (0.71-0.99)	●		.04
Axilla or groin	370	46.3 (13.7)	337	24.7 (8.0)	0.51 (0.44-0.60)	●		<.001
Perirectal	412	51.5 (13.5)	473	34.1 (11.1)	0.65 (0.57-0.74)	₩		<.001
Any MRSA	343	42.9 (11.2)	422	29.8 (9.3)	0.68 (0.59-0.79)	₩		<.001
Nares	236	29.5 (7.3)	360	25.1 (8.6)	0.84 (0.71-0.99)	<b>⊢</b>		.04
Axilla or groin	247	30.9 (10.5)	176	13.1 (6.5)	0.40 (0.33-0.49)	⊢●⊢		<.001
Perirectal	207	25.9 (9.2)	142	10.8 (5.5)	0.39 (0.31-0.48)	<b>⊢●</b> ⊢		<.001
Any VRE	125	15.6 (7.6)	134	9.4 (6.7)	0.61 (0.48-0.78)	— <b>⊢</b>		.001
Axilla or groin	68	8.5 (5.4)	37	2.7 (3.3)	0.32 (0.21-0.48)	<b>⊢</b> •−		<.001
Perirectal	114	14.3 (7.8)	120	8.4 (5.8)	0.60 (0.47-0.78)	<b>⊢</b>		.002
Any ESBL	269	33.6 (17.2)	356	25.5 (10.5)	0.74 (0.63-0.87)	<b>⊢</b>		.003
Axilla or groin	167	20.9 (12.0)	163	12.1 (6.1)	0.55 (0.44-0.68)	<b>⊢</b>		<.001
Perirectal	248	31.0 (16.5)	310	22.3 (9.5)	0.70 (0.59-0.83)	—   <del> </del>		<.001
Any CRE	17	2.1 (4.3)	22	1.6 (2.8)	0.78 (0.41-1.47)		—	.44
Axilla or groin	12	1.5 (3.5)	16	1.1 (2.0)	0.79 (0.37-1.68)		——	.54
Perirectal	8	1.0 (2.1)	11	0.9 (1.5)	0.83 (0.33-2.09)	-		.70

OR (95% CI)

Gussin G et al. JAMA Online ahead of print. April 1, 2024 For internal use only, not for distribution.

Figure 1. MDRO Point Prevalence (Screening) Among Facilities Participating in the Regional Decolonization Collaborative, Baseline and End of Intervention

	Baseline		Intervention				
Colonization	No. of MDRO- positive persons	Mean (SD) prevalence across facilities, %	No. of MDRO- positive persons	Mean (SD) prevalence across facilities, %	OR (95% CI)	Less likely to be More likely to be MDRO-positive	
ong-term acute care	facilities						
Any MDRO	120	80.0 (7.2)	80	53.3 (13.3)	0.67 (0.50-0.89)	<b>⊢●</b>	.01
Nares	35	23.3 (9.5)	25	16.7 (8.3)	0.71 (0.43-1.20)	<b>⊢</b>	.20
Axilla or groin	91	60.7 (9.0)	36	24.0 (6.0)	0.40 (0.27-0.58)	<b>⊢ → →</b>	<.001
Perirectal	109	72.7 (9.5)	68	45.3 (12.9)	0.62 (0.46-0.85)	<b>⊢●</b>	.003
Any MRSA	49	32.7 (8.3)	30	20.0 (10.6)	0.61 (0.39-0.97)	<b>├</b>	.04
Nares	35	23.3 (9.5)	25	16.7 (8.3)	0.71 (0.43-1.20)	<b>⊢</b>	.20
Axilla or groin	25	16.7 (3.1)	12	8.0 (2.0)	0.48 (0.24-0.96)	<u> </u>	.04
Perirectal	28	18.7 (11.0)	11	7.3 (7.6)	0.39 (0.20-0.79)	<b>├</b>	.01
Any VRE	83	55.3 (5.0)	38	25.3 (10.1)	0.46 (0.31-0.67)	<b>⊢</b>	<.001
Axilla or groin	55	36.7 (6.4)	13	8.7 (3.1)	0.24 (0.13-0.43)		<.001
Perirectal	78	52.0 (5.3)	38	25.3 (10.1)	0.49 (0.33-0.72)	<b>⊢</b>	<.001
Any ESBL	58	38.7 (9.0)	39	26.0 (10.4)	0.67 (0.45-1.01)	<b>⊢</b>	.06
Axilla or groin	40	26.7 (5.8)	18	12.0 (3.5)	0.45 (0.26-0.79)	<b>├</b>	.01
Perirectal	52	34.7 (8.1)	34	22.7 (11.7)	0.65 (0.42-1.01)	<b>⊢</b>	.06
Any CRE	13	8.7 (1.2)	10	6.7 (3.1)	0.77 (0.34-1.76)		.53
Axilla or groin	11	7.3 (1.2)	5	3.3 (3.1)	0.45 (0.16-1.31)		.14
Perirectal	11	7.3 (1.2)	10	6.7 (3.1)	0.91 (0.38-2.15)	<b>—</b>	.83

OR (95% CI)


Gussin G et al. JAMA Online ahead of print. April 1, 2024 For internal use only, not for distribution.

Figure 1. MDRO Point Prevalence (Screening) Among Facilities Participating in the Regional Decolonization Collaborative, Baseline and End of Intervention

	Baseline		Intervention				
Colonization	No. of MDRO- positive persons	Mean (SD) prevalence across facilities, %	No. of MDRO- positive persons	Mean (SD) prevalence across facilities, %	OR (95% CI)	Less likely to be More likely to be MDRO-positive	
Hospitals with patier	nts in contact precau	utions					
Any MDRO	474	64.1 (8.5)	409	55.4 (13.8)	0.86 (0.75-0.98)	⊬⊕H	.03
Nares	221	29.9 (6.5)	220	29.7 (10.9)	1.00 (0.83-1.21)	<b>⊢</b> ∳⊢l	.97
Axilla or groin	242	32.9 (10.8)	167	22.5 (14.1)	0.69 (0.57-0.84)	<b>⊢●</b> ⊢	<.001
Perirectal	363	49.2 (9.0)	273	37.2 (13.2)	0.75 (0.64-0.88)	<b>⊢●</b> ⊢	<.001
Any MRSA	265	35.9 (7.6)	252	34.2 (13.3)	0.95 (0.80-1.13)	⊢ <del>•</del> ⊢	.60
Nares	221	29.9 (6.5)	220	29.7 (10.9)	1.00 (0.83-1.21)	⊢ <del>•</del> ⊢	.97
Axilla or groin	104	14.1 (7.5)	93	12.8 (11.0)	0.89 (0.68-1.18)	<b>⊢●</b>	.43
Perirectal	105	14.3 (6.7)	88	12.1 (9.2)	0.84 (0.64-1.12)	<b>⊢</b> • <del>!</del>	.24
Any VRE	185	25.1 (7.1)	141	19.3 (11.9)	0.76 (0.61-0.94)	<b>⊢●</b> ⊢	.01
Axilla or groin	101	13.8 (6.6)	49	6.7 (5.9)	0.48 (0.34-0.68)	<b>⊢●</b>	<.001
Perirectal	175	23.8 (6.7)	134	18.4 (11.6)	0.76 (0.61-0.95)	<b>⊢●</b> ⊢	.02
Any ESBL	202	27.3 (6.8)	143	19.3 (6.0)	0.69 (0.55-0.87)	<b>⊢●</b> ⊢	.001
Axilla or groin	97	13.1 (5.9)	49	6.7 (3.4)	0.71 (0.57-0.88)	<b>⊢●</b> ⊢	.002
Perirectal	181	24.5 (5.5)	125	16.9 (6.6)	0.51 (0.36-0.71)	<b>⊢●</b> ─	<.001
Any CRE	18	2.4 (2.3)	15	2.1 (3.0)	0.83 (0.42-1.65)	<b>—</b>	.60
Axilla or groin	6	0.8 (1.3)	8	1.1 (1.6)	1.34 (0.46-3.86)	<b>—</b>	∃ .59
Perirectal	17	2.3 (2.0)	13	1.8 (2.5)	0.76 (0.37-1.57)	<b>├</b>	.46
		ne ahead of pri			0.1		4
For in	nternaliuse	only not fo	r distributi	on		OR (95% CI)	

## Impact: NH Hospitalizations Due to Infection

Figure 5. Monthly Infection-Related Hospitalization Rates Among Nursing Homes Residents in Participating (Decolonization) vs Nonparticipating Nursing Homes



Gussin G et al. JAMA Online ahead of print. April 1, 2024 For internal use only, not for distribution.

### Impact: NH Hospitalization-Related Costs & Deaths

· -				<u> </u>			
	Costs Assoc	iated with Infect	ion-Related H	lospitalization			
		Costs		Adjusted Analysis <sup>b</sup>			
Decolonization Group	_	Resident Days	Clustered	Group-By-Period Interaction Effect			
Group	Baseline	Intervention	Cost Ratio	% Reduction (95% CI)	P-value		
Participant	\$64,651	\$55,149	0.96	-26.8%	<0.001		
Non-Participant	\$55.151	\$59,327	1.31	(-26.7, -26.9)	<0.001		
	Deaths Asso	ciated with Infed	tion-Related	Hospitalization			
	E	vents	Adjusted Analysis <sup>b</sup>				
Decolonization Group		Resident Days	Clustered	Interaction Effect			
	Baseline	Intervention	Hazard Ratio	% Reduction (95% CI)	P-value		
Participant	0.29	0.25	0.62	-23.7%	0.006		
Non-Participant	0.23	0.24	0.81	(-4.5, -43.0)	0.000		

### The Protect Trial

The NEW ENGLAND JOURNAL of MEDICINE

#### ORIGINAL ARTICLE

### Decolonization in Nursing Homes to Prevent Infection and Hospitalization

L.G. Miller, J.A. McKinnell, R.D. Singh, G.M. Gussin, K. Kleinman, R. Saavedra, J. Mendez, T.D. Catuna, J. Felix, J. Chang, L. Heim, R. Franco, T. Tjoa, N.D. Stone, K. Steinberg, N. Beecham, J. Montgomery, D.A. Walters, S. Park, S. Tam, S.K. Gohil, P.A. Robinson, M. Estevez, B. Lewis, J.A. Shimabukuro, G. Tchakalian, A. Miner, C. Torres, K.D. Evans, C.E. Bittencourt, J. He, E. Lee, C. Nedelcu, J. Lu, S. Agrawal, S.G. Sturdevant, E. Peterson, and S.S. Huang

Miller LG et al. NEJM 2023 (Nov 9); 389:1766-1777

### **The Protect Trial**

#### **Pragmatic Trial**

- 28 nursing homes
- Involved nearly 14,000 residents
- All activities performed by usual nursing home staff

#### **Group 1: Routine Care**

Usual soap for showering/bathing

#### **Group 2: Decolonization**

- CHG for all bathing/showering
- Nasal iodophor for all residents, M-F twice daily, every other week

# **CHG** for All Routine Bathing and Showering

- Liquid CHG for showering
  - 4% rinse off CHG
- CHG cloths for bed bathing
  - 2% leave on CHG





2% cloths for bath

# **Iodophor for Nasal Decolonization**

- 10% povidone-iodine swabs (iodophor) to each nostril
- Facility-wide universal strategy
- Twice daily for 5 days
- On admission and M-F every other week



# MDRO Carriage Reduction (Skin/Nares)

MDRO or sample	Prevalence in the Routine-Care Group		Prevale: Decoloniz	Risk Ratio (95% CI)†	
	Baseline $(N = 700)$	Intervention (N=650) percent (number o	Baseline (N=700) f positive samples)	Intervention (N = 550)	
Any MDRO	48.3 (338)	47.2 (307)	48.9 (342)	32.0 (176)	0.70 (0.58–0.84)
Any MRSA	37.6 (263)	36.9 (240)	36.4 (255)	25.1 (138)	0.73 (0.59–0.92)
Nostril swab sample	29.1 (203)	27.1 (176)	29.9 (209)	22.0 (121)	0.81 (0.62–1.05)
Skin swab sample	26.1 (183)	25.4 (165)	22.6 (158)	11.6 (64)	0.58 (0.42–0.79)
VRE	5.9 (41)	5.1 (33)	8.3 (58)	2.2 (12)	0.29 (0.14–0.62)
ESBL producer	15.9 (111)	17.9 (116)	16.7 (117)	9.2 (51)	0.50 (0.34–0.75)
CRE	1.4 (10)	0.6 (4)	0.4 (3)	0.4 (3)	3.53 (0.44–28.52)

Miller LG et al. NEJM 2023 (Nov 9); 389:1766-1777

### **Trial Outcomes**

Outcome	Infection-Related Hospitalization	Any Hospitalization
Reason among hospitalizations Reason among discharges	17% reduction in infection—related hospitalizations, among hospitalized	15% reduction in hospitalizations, among discharged
Per 1,000 Resident Days	<b>31% reduction</b> in infection—related hospitalizations per 1,000 resident days	18% reduction in hospitalizations per 1,000 resident days
Number Needed to Treat (NNT)	9.7 residents	8.9 residents

1.9 infection-related hospitalizations averted per month per 100-bed nursing home

# **Implementation Steps**

### **Step 1: Assess Readiness for Adoption**

- Nursing home leadership sees value, need to reduce
  - > Infections
  - Hospitalizations
  - MDRO pathogens (65% of residents colonized, common outbreak source)
    - Gram positives: MRSA, VRE
    - Gram negatives: ESBL, CRE, CRAB
    - o Fungi: *C. auris*

#### **Support Options:**

- ✓ Share 2-page evidence sheet
- ✓ Share NACCHO recorded webinar on decolonization evidence
- ✓ Request special webinar presentation by UCI to nursing homes in your area For internal use only, not for distribution.

#### **Decolonization Benefits in Nursing Homes**

The below results are from the Protect Trial and were redemonstrated during the SHIELD regional intervention, both of which involved pragmatic adoption of decolonization in nursing homes.

#### Residents less colonized by MDROs

$\checkmark$	Any MDRO	30% reduction
--------------	----------	---------------

✓ MRSA 27% reduction

✓ VRE **71% reduction** 

✓ ESBL **50% reduction** 

Decolonization results in fewer MDROs, less MDRO colonization, and fewer residents on contact precautions

#### Residents less likely to be hospitalized


- ✓ Overall hospitalization rate 18% reduction
  - 1 hospitalization prevented for every
     9 residents treated
- ✓ Infection hospitalization rate 31% reduction
  - 1 infection-related hospitalization prevented for every 10 residents treated

Decolonization prevents 1.9 infection-related hospitalizations *per month* per 100 beds

# **Step 2: Agree to Investment for Quality & Cost Savings**

- Universal decolonization requires leadership support to
  - > Adopt as Quality Assurance/Performance Improvement (QAPI) Program
  - Prepare for a campaign
  - Purchase products
  - Designate champions












#### **Options:**

✓ Share 2-page cost savings sheet

#### **Decision Making and Costs**

#### Estimated Monthly Savings for a 100-Bed Nursing Home = \$860



- a. Switching from regular soap to CHG soap
  - Assumes baseline use of 50 gallons regular soap/month at \$20/gallon (gal) = \$1,000/mo
  - Assumes 35 gal of CHG at \$60/gal = \$2,100/mo (CHG protocol uses less volume of soap)
  - Difference = \$1,100 added product cost/month
- b. **Purchasing nasal iodophor.** \$6.95 for box of 50 swabs. At perfect compliance, a 100-bed nursing home uses: 2 swabs (one/nostril) x 2 times/day x 10 days/month x 100 residents = 4,000 swabs (80 boxes). Studies suggest 70% compliance, at cost of \$390/mo.

#### **Decision Making and Costs**

#### Estimated Monthly Savings for a 100-Bed Nursing Home = \$860



- c. Switching from chlorine to peroxide bleach. Estimated costs are for 20 gal/month. Chlorine bleach: \$65/5-gal or \$260/mo. Peroxide: \$107/5-gal or \$428/mo. Difference per month is \$168. Some laundry contracts with a fixed price per bed do not incur additional cost when switching from chlorine to peroxide bleach.
- d. **Decolonization prevents 1.9 infection-related hospitalizations per month per 100 beds.** A 100-bed nursing home would save \$2,518 per month by preventing 5.3 bed-hold days per hospitalization at \$250 per day.

## **Step 3: Checklist**

- ☐ Purchase product
  - 4% Chlorhexidine (CHG) (gallon formulation for humans, not pets)
  - 10% Povidone-lodine swab sticks (generic)
  - Non-cotton disposable dry wipes or cloths
    - Note: Tena non-cotton dry cloths work particularly well
    - Cotton binds CHG and does not release well to skin
- ☐ Switch from chlorine to peroxide bleach
  - Chlorine and CHG can mix in the laundry and leave a brown stain
  - Ensure several laundry runs with peroxide occur before CHG adopted
- ☐ Confirm lotions and skin products are CHG compatible
  - Call manufacturers to confirm skin products are compatible. Because CHG is widely used in hospitals, common healthcare manufacturers have tested their products against CHG. If not, several same-priced alternatives exist.

# **Step 4: Prepare to Launch**

- Benefit tied to ensuring proper process
  - Designate MD, RN, LVN, and CNA champions
  - Create a training plan
  - Plan to report feedback and improvement to champions, QA meeting
  - Plan to track outcomes

## **Support Options:**

- ✓ Access nursing home toolkit at ucihealth.org/shield
- ✓ Print handouts and training materials
- ✓ Request train-the-trainer webinar presentation
- ✓ Schedule dates for direct-to-staff training sessions

# **Nursing Home Decolonization Toolkit**

Step 1: Adopt SHIELD program as Quality Assurance Performance Improvement (QAPI)

- 1. QAPI Project Documentation Form (PDF) (DOC)
- 2. Universal Plan of Care (PDF) (DOC)
- 3. Resident Plan of Care (PDF) (DOC)
- 4. Pre-Launch Checklist for the Infection Preventionist (PDF) (DOC)
- Step 2: What to Expect? (PDF) (DOC)
- Step 3: Communication to Residents
  - 1. Admission Packet Letter (PDF) (DOC)
  - 2. Resident/Ombudsman Information Sheet (PDF) (DOC
- Step 4: Products & Protocols
  - 1. Products (PDF) (DOC)
  - 2. CHG Compatibility (PDF) (DOC)
  - 3. Protocol: Bed Bath With CHG Cloths (PDF) (DOC)
  - 4. Protocol: Bed Bath With CHG Liquid (PDF) (DOC)
  - 5. Protocol: Showering With CHG (PDF) (DOC)
  - 6. Protocol: Nasal Iodophor (PDF) (DOC)
  - 7. Order Set Examples (PDF)
  - 8. Admission SHIELD Checklist (PDF) (DOC)

## ucihealth.org/shield

- Step 5: Staff Education & Training
  - 1. Paper or Computer Based Training (PDF) (PPT)
  - 2. Staff Post-Training Test and Answer Key: Basin Bed Bathing
  - 3. Staff Post-Training Test and Answer Key: CHG Cloths (PDF)
  - 4. Physician and Staff Notification Flyer (PDF) (DOC)
  - 5. Staff Handouts for CHG Bathing/Showering (PDF) (PUB)
  - 6. Staff Handout for Basin Bed Bathing With CHG (PDF) (PUB)
  - 7. Staff Handout for Nasal Iodophor (PDF) (PUB)
  - 8. Staff Huddle Reminder Documents (PDF) (DOC)
  - 9. FAQ: General (PDF) (DOC)
  - 10. FAQ: Nasal Iodophor (PDF) (DOC)
  - 11. FAQ: CHG for Bathing (PDF) (DOC)
  - 12. FAQ: Wound Care (PDF) (DOC)
  - 13. FAQ: Do and Don't (PDF) (DOC)

### Step 6: Resident Education & Training

- 1. Resident Handout for CHG Bed Bath (PDF) (PUB)
- 2. Resident Handout for CHG Shower (PDF) (PUB)
- 3. Resident Handout for Nasal Iodophor (PDF) (PUB)
- 4. Waterproof Shower Poster for Residents (PDF) (DOC)
- 5. Resident Talking Points: CHG (PDF) (DOC)
- 6. Resident Talking Points: Iodophor (PDF) (DOC)


### Step 7: Skills Assessments and Compliance Checks

- 1. CHG Cloth Skills Assessment Checklist (PDF) (DOC)
- 2. CHG Liquid Bed Bath Skills Assessment Checklist (PDF) (DOC)
- 3. Resident Self-Showering Assessment (PDF) (DOC)
- 4. Resident Self-Bed Bath Assessment (PDF) (DOC)

### Step 8: Safety and Side Effects


- 1. Safety and Side Effects (PDF) (DOC)
- 2. Side Effect Tracking Form (PDF) (DOC)

# **Nursing Home Decolonization Toolkit**




Armpit, groin, between fingers/toes

Avoid eves, mouth, & ear canals



- 1. Prepare 4% liquid CHG, a measuring cup, a bed basin, and 6 disposable wipes (more if needed).
- 2. Dispense 1/2 cup of 4% CHG liquid into
- 3. Add 1/2 cup of water. Do not dilute more than equal part of water to CHG.



- 4. Soak wipes in basin and wring before use. Do not place back into basin after
- 5. Firmly massage skin with wipes.
- 6. Clean over semi-permeable dressings.
- 7. Clean 6 inches of lines, tubes, and drains.

#### REMINDERS

- · Your enthusiasm helps residents understand why CHG is important
- · Bathing on admission removes germs to protect the resident and nursing home

STAFF


- · CHG works for 24 hours to kill germs
- · Firmly massage CHG onto skin
- Clean 6 inches of lines, drains, tubes
- · Safe on surface wounds, rashes, burns
- · Use only CHG-compatible lotions
- · If barrier protection needed, apply CHG then apply barrier protection

#### Clean all skin areas with attention to:

- Neck
- All skin folds
- Skin around all devices (line/tube/drain)
- Wounds unless deep or large
- Armpit, groin, between fingers/toes

ucihealth.org/shield

### Apply Chlorhexidine WITH FIRM MASSAGE to remove bacteria



## THIS IS a PROTECTIVE BATH

Do not use soap which can inactivate CHG

## For internal use only, not for distribution.

## **Decolonization FAQs**



#### Frequently Asked Questions Chlorhexidine for Bathing

#### What is chlorhexidine (CHG) and how safe is it?

CHG is an over-the-counter antiseptic agent that helps to reduce the an germs on your skin, including antibiotic-resistant germs such as MRSA. CH cleared for this purpose. CHG has an excellent safety profile and has beer healthcare for over 60 years. Although allergic reactions to CHG are rare, cocur. Most of them are limited to the site of application and including irritation, rash or redness, which resolves with discontinuation.

#### What if my resident refuses a bath?

Residents have the right to refuse any medical care. Staff need to assess the resident is refusing at this time (e.g. tired, in pain, irritable), or whe resident is refusing all together and if the resident understands the rea the value of the protective bath (e.g. to prevent infection due to MRSA at bacteria). Of course, the resident does not wish to have this done, it is the to refuse.

If the staff member believes that the resident is stating that it's not the bethen the staff should offer and encourage a bath at a later time. Ren

#### Is it okay for my residents to shave and use deodorant?

Even though shaving cream and deodorant may inactive CHG, we understand that residents will want to shave and use deodorant. If shaving is performed, ensure that shaving cream only contacts body area that is being shaved.

### What if my resident has an incontinence episode or needs freshening up throughout the day?

CHG cloths should be used for all bathing purposes, including full-body bathing, cleaning after soiling, or any other reasons for additional cleaning such as freshening up. Do not use soap to cleanse incontinent residents because soap can inactivate CHG. First remove urine/stool with usual incontinence wipes or cloths and water. Next, clean with CHG and allow to air dry. Finally, apply CHG compatible barrier protection over the area. Repeat as often as needed throughout the day.

#### My resident reports that their skin feels sticky after the bath.

The sticky feeling is due to the moisturizing ingredients in the CHG cloths and it will go away as it dries. The cloths contain aloe vera.

#### Is it safe to use on the perineum?

Yes, CHG is safe to use on the perineum and external mucosa.

#### Is CHG safe to use on lines, tubes, and drains?

Yes, it is very important to clean lines, tubes, and drains in addition to the skin surrounding these devices in order to prevent infection. The 6 inches of any tube, drain, or line nearest the body should be cleaned. Non-absorbable (non-gauze) dressings should also be wiped over with the CHG cloth after the skin is cleaned.

#### Should gloves be worn or changed during bathing with CHG cloths?

Yes. Although it is safe to handle the CHG cloths with bare skin, gloves should be worn for bathing residents. If gloves become soiled, they should be changed.



#### Frequently Asked Questions Wound Care

The majority of our nurses and certified nursing assistants (CNAs) feel comfortable using chlorhexidine (CHG) cloths on superficial wounds,

but some do not. How would you suggest easing their concerns?
Remind all nursing staff that CHG cloths are safe to use on superficial wounds and
stage 1 & 2 decubitus ulcers. Using the buddy system, in which nursing staff who
are comfortable using CHG on superficial wounds buddy up with staff who are
less comfortable, can also help.

#### Should I be concerned about CHG having a stinging effect on wounds?

Antiseptic over-the-counter products often contain alcohol and will sting when applied to wounds. In contrast, CHG cloths do not contain alcohol and will not sting. In fact, CHG cloths contain dimethicone and aloe vera which are moisturizers and actually have a soothing effect on the superficial wound area.

#### Will CHG be absorbed if I put it on a wound?

There is minimal to no systemic absorption when using CHG on a superficial wound. In addition, the CHG may be particularly important to get rid of bacteria in an open wound and prevent infection.

#### For what types of wounds is CHG safe?

CHG can be gently applied to any superficial wound, including stage 1 and 2 decubitus ulcers, friable skin/rash, and superficial burns. We do not recommend

SHIELD

Shared
Healthcare
Intervention to
Eliminate
Life-threatening
Dissemination of MDROs

Frequently Asked Questions Nasal Iodophor

#### odophor and how safe is it?

is another name for "povidone-iodine," which is an over-the-counter that is most known for its use in cleaning scrapes, cuts, and wounds and infections. It is also FDA cleared for use in the nose. Povidone-iodine is e-counter antiseptic product. It has been used in healthcare for over 60 al iodophor has been used in thousands and thousands of patients prior f, in ICUs, and in nursing homes as a way to prevent MRSA and

methicillin-sensitive *Staphylococcus aureus* (MSSA) infection. Side effects from iodophor are uncommon, mild and resolve with discontinuation. They may include nasal irritation, runny nose, and sneezing. As with any product, rare serious allergic reactions can occur.

#### What is the purpose of putting it in the nose?

lodophor removes germs that commonly live in the nose, including methicillinresistant *Staphylococcus aureus*, or MRSA. Many studies have shown that nursing home residents are much more likely to harbor MRSA than people in the community or patients in hospitals. In fact, recent data across many nursing

3

# **Decolonization Success Depends on Application**

- Lack of training shown to yield no benefit
- Training pearls for CHG
  - Massage firmly
  - Avoid cotton cloths
  - Clean wounds, devices, breaks in skin
  - Check lotion, skin product compatibility
  - 4% rinse-off CHG, 2% leave-on (air dry)

Chlorhexidine Only Works If Applied Correctly: Use of a Simple Colorimetric Assay to Provide Monitoring and Feedback on Effectiveness of Chlorhexidine Application

Laura Supple, BS; <sup>1</sup> Monika Kumaraswami, MD; <sup>1</sup> Sirisha Kundrapu, MD, MS; <sup>2</sup> Venkata Sunkesula, MD, MS; <sup>2</sup> Jennifer L. Cadnum, BS; <sup>2</sup> Michelle M. Nerandzic, BS; <sup>1</sup> Myreen Tomas, MD; <sup>3</sup> Curtis J. Donskey, MD<sup>2,3</sup>

We used a colorimetric assay to determine the presence of chlorhexidine on skin, and we identified deficiencies in preoperative bathing and daily bathing in the intensive care unit. Both types of bathing improved with an intervention that included feedback to nursing staff. The assay provides a simple and rapid method of monitoring the performance of chlorhexidine bathing.

Infect Control Hosp Epidemiol 2015;00(0):1-3

Popovich KJ Int Care Med 2010;36(5):854-8 Supple L ICHE 2015;36(9):1095-7



### **CHG Cloth Observation Checklist**

Please complete for THREE different staff per unit

Indiv	/idual (	Giving CHG Bath
Pleas	e indica	te who performed the CHG bath.
□ N	ursing A	Assistant (CNA) Nurse Other:
Obse	erved C	HG Bathing Practices
		the appropriate response for each observation.
□ Y	□ N	Patient received CHG cloth bathing handout
□ Y	□ N	Patient told that bath is a no rinse cloth that provides protection from germs
<b>□</b> Y	□ N	Provided rationale to the patient for not using soap at any time while in unit
□ Y	□ N	Massaged skin firmly with CHG cloth to ensure adequate cleansing
□ Y	□ N	Cleaned face and neck well
□ Y	□ N	Cleaned between fingers and toes
□ Y	□ N	Cleaned between all folds in perineal and gluteal area
□ Y	□ N	■ N/A Cleaned occlusive and semi-permeable dressings with CHG cloth
□ Y	□ N	■ N/A Cleaned 6 inches of all tubes, central lines, and drains closest to body
☐ Y	□ N	N/A Used CHG on superficial wounds, rash, and stage 1 & 2 decubitus ulcers
□ Y	□ N	■ N/A Used CHG on surgical wounds (unless primary dressing or packed)
□ Y	□ N	Used all 6 cloths (more if needed)
□ Y	□ N	Allowed CHG to air-dry / does not wipe off CHG
□ Y	□ N	Disposed of used cloths in trash /does not flush
Que	r <b>y to B</b> a	athing Assistant/Nurse
1. Do	you eve	er use soap in conjunction with a CHG bathing cloth? If so, when?
2. Do	you rea	pply CHG after an episode of incontinence has been cleaned up?
3. Are	you co	mfortable applying CHG to superficial wounds, including surgical wounds?
4. Are	you co	mfortable applying CHG to lines, tubes, drains and non-gauze dressings?

## **Decolonization Dos and Don'ts**

### DO

- Begin decolonization on admission to remove germs as soon as possible
- Use chlorhexidine (CHG) for all bathing/showering needs for all residents
- Use 2% no-rinse CHG cloths for bed baths or 4% rinse-off liquid CHG for showers
- Use CHG for regular bathing during resident's entire nursing home stay
- Massage CHG onto skin for best effect
- Use CHG on lines, tubes, drains, and over non-gauze dressings
- Use on superficial wounds and rashes to remove germs
- Use nasal iodophor treatment twice a day for a 5-day period every other week


### DON'T

- Do NOT get CHG into eyes or ears
- Do NOT wipe off after applying CHG cloths. Let air dry.
- Do NOT apply dressings when skin is still sticky. Wait until fully dry.
- Do NOT flush CHG cloths. Place in trash.
- Do NOT use cotton cloths for showering it binds CHG and does not release well
- Do NOT use iodophor and/or CHG on resident if resident is allergic

### REFER TO NURSING PROTOCOL FOR STEP-BY-STEP INSTRUCTIONS


# **Training Video for CHG Bathing**


- CHG bathing and showering instructions
- Scenarios for how to encourage patients to accept bath
- Commonly missed and important protocol details (i.e., cleaning lines, tubes, drains, superficial wounds)
- Instructions for patients wishing to self-bathe



https://www.ahrq.gov/hai/tools/abate/index.html







## **Step 5: Process and Practice**

Select Launch Date ☐ Pre-Launch Facility-wide Training Days CNAs LVN/RNs • See toolkit modules and videos to be used with in-person train-the-trainer ☐ Pre-Launch Skin Check to avoid attributing existing conditions to CHG Launch ☐ Provide Admission Packet materials on routine decolonization (see toolkit) ☐ Post-Launch Feedback on Bathing Quality Toolkit assessment tool (few times weekly early in campaign) Ongoing Training for new hires

## **Support Options:**

- ✓ Access nursing home toolkit at ucihealth.org/shield
- ✓ Schedule UCI on-site visit 2 or 3 months after launch for troubleshooting, reinforcement For internal use only, not for distribution.

# **Step 6: Outcomes**

## **Track Some of the Following Benefits:**

- Skin checks
- MDRO prevalence
- Contact precautions
- Antibiotic use
- Infections
- Hospitalizations due to infection

# **Summary: Decolonization**

- Topical decolonization of skin and nose repeatedly shows benefit:
  - ✓ Reduces MDROs, Gram+ and Gram-
  - ✓ Reduces bloodstream infections in hospitals
  - ✓ Reduces hospitalizations from serious infections in nursing homes, and reduces related costs and deaths
- Universal application most effective in high-risk populations
- Quality of training and application matters
- Free, online tools can help with implementation



For internal use only, not for distribution.